Zynex Inc.  

(Public, OTCMKTS:ZYXI)   Watch this stock  
Find more results for OTC:ZYXI
0.000 (0.00%)
Jan 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.06 - 0.51
Open     -
Vol / Avg. 0.00/14,994.00
Mkt cap 5.47M
P/E     -
Div/yield     -
EPS -0.36
Shares 31.27M
Beta -7.47
Inst. own 0%
Nov 7, 2014
Q3 2014 Zynex Inc Earnings Call - Webcast
Nov 7, 2014
Q3 2014 Zynex Inc Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 6.09% -33.85%
Operating margin 9.36% -35.05%
EBITD margin - -31.18%
Return on average assets 10.58% -34.02%
Return on average equity - -86.24%
Employees 153 -
CDP Score - -


United States - Map
+1-303-7034906 (Phone)
+1-800-4956695 (Fax)

Website links


Zynex, Inc. operates under three primary business segments: Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical engineers, manufactures, markets and sells its design of electrotherapy medical devices used for pain management and rehabilitation. Zynex Medical�s product lines are cleared by the United States Food and Drug Administration (FDA) and sold worldwide. Zynex NeuroDiagnostics, sells the Company's NeuroMove device designed to help stroke and spinal cord injury patients and is seeking opportunities into markets for electromyogram (EMG), electroencephalogram (EEG), sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. As of January 30, 2012, Zynex Monitoring Solutions was in the development-stage. In February 2012, it announced the creation of a European wholly owned subsidiary in Denmark. In June 2012, the Company acquired ZYNEX.com Internet domain.

Officers and directors

Thomas Sandgaard Chairman of the Board, President, Chief Executive Officer
Age: 54
Brian Alleman Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Age: 58